Asco 2020 movers – cell therapy companies dominate the risers

Asco 2020 movers – cell therapy companies dominate the risers

Source: 
EP Vantage
snippet: 

Despite going virtual this year the biggest annual cancer conference, Asco, still managed to exert a marked influence over share prices. And it was cell therapy companies that received the biggest boost, with five developers notching up substantial gains in the weeks after abstracts were released.

Topping the table is Adaptimmune, which saw its valuation more than double over this period. The predictable equity offering followed, as did fundraisings from other cell therapy researchers: Adaptimmune, Allogene and Iovance have completed impressive secondaries to bring in $226m, $550m and $604m respectively in the past week.